Blockade of the checkpoint PD-1 by its ligand PD-L1 and the immuno-oncological drugs pembrolizumab and nivolumab

Superposition of the crystallographic structures of the receptor PD-1 in complex with the natural ligand PD-L1, as well as to the monoclonal antibodies pembrolizumab and nivolumab.